TG Therapeutics Earnings Overview
TG Therapeutics (NASDAQ: TGTX) is set to release its upcoming quarterly earnings report. Investors are eagerly awaiting details that could affect stock performance and overall market sentiment.
Expected Earnings Per Share
Market analysts forecast an earnings per share (EPS) of $0.22 for TG Therapeutics. This mark will serve as a benchmark for investors as the company reveals its financial status.
Importance of Guidance
Prior to the earnings announcement, it’s essential for investors to note that company guidance can significantly influence stock valuation. Positive guidance could lead to favorable investor sentiment, pushing the shares higher.
Review of Previous Earnings
In the previous quarter, TG Therapeutics fell short of expectations, with an EPS that was $0.13 below analysts' forecasts. Following this announcement, the stock experienced a 1.11% decline.
Past Financial Performance
Here’s a glance at TG Therapeutics’ previous quarterly performances and the corresponding stock price changes:
For Q2 2025, the EPS estimate was $0.30, while the actual result was $0.17. The shares garnered a -1.00% price change following this release. In Q1 2025, an EPS of $0.03 was reported against a forecast of $0.17, leading to a more significant -7.00% drop.
Current Stock Performance
As of October 30, shares of TG Therapeutics traded at $34.02, reflecting a remarkable increase of 44.95% over the last year. This trend is encouraging for long-term investors who anticipate sustained growth.
Analyst Ratings and Company Insights
When it comes to investment decisions, understanding market sentiment is crucial. Analysts have assessed TG Therapeutics and rendered a consensus rating of Buy, with a one-year price target averaging $57.5, which signifies a potential upside of 69.02%.
Industry Comparisons
In the biotech sector, it's vital to assess how TG Therapeutics stands against its peers. Analyzing ratings for competitors like CRISPR Therapeutics and Krystal Biotech gives a better perspective on market positioning:
- CRISPR Therapeutics enjoys a Buy rating with an estimated price target of $73.0, indicating an upside of 114.58%.
- Similarly, Krystal Biotech has earned a Buy rating, and its estimated price target stands at $222.67 with a staggering upside of 554.53%.
Peer Comparison Summary
The comparative analysis of TG Therapeutics with industry peers like CRISPR Therapeutics and Krystal Biotech highlights some key metrics:
Key Company Metrics
| Company | Consensus Rating | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| TG Therapeutics | Buy | 92.13% | $122.21M | 10.97% |
| CRISPR Therapeutics | Buy | 0.00% | $-45.15M | -11.78% |
| Krystal Biotech | Buy | 36.65% | $88.88M | 3.79% |
In terms of revenue growth, TG Therapeutics stands out within the sector, showcasing not only leading growth but also a robust gross profit margin compared to its peers.
Exploring TG Therapeutics
TG Therapeutics is a biopharmaceutical firm committed to developing innovative therapies for B-cell diseases. The company has multiple products in development, including BRIUMVI, approved for treating relapsing forms of multiple sclerosis, and several promising candidates aimed at B-cell disorders.
Financial Health Examination
Market Capitalization: The market capitalization of TG Therapeutics reflects its positioning within the industry as a formidable player.
Revenue Growth: With a reported revenue growth rate of 92.13%, TG Therapeutics showcases considerable potential for profitability within its field.
Net Margins and Debt Indicators: The net margin hovers around 19.97%, highlighting efficient cost management. However, the debt-to-equity ratio stands at 0.92, indicating considerable leverage that could impact future financing and operational flexibility.
Preparing for the Future
As the earnings report approaches, both investors and analysts will scrutinize the details closely. The outcomes will not only influence short-term trading strategies but may also affect the longer-term development of TG Therapeutics as a leader in its field.
Frequently Asked Questions
What are the expected earnings for TG Therapeutics?
Analysts expect an EPS of $0.22 for the upcoming earnings report.
How did TG Therapeutics perform last quarter?
Last quarter, the company missed EPS estimates by $0.13, leading to a drop in stock price.
What is the current price target for TG Therapeutics?
The average price target from analysts for TG Therapeutics is $57.5, indicating a significant upside potential.
How has TG Therapeutics's stock performed over the past year?
Over the last 52 weeks, shares have risen by 44.95%, reflecting strong market performance.
What is TG Therapeutics focusing on developing?
The company is concentrating on novel therapies for B-cell diseases, including BRIUMVI for multiple sclerosis and treatments in development for other B-cell disorders.
